Literature DB >> 6794746

Intraperitoneal insulin in uraemic diabetics undergoing continuous ambulatory peritoneal dialysis.

A Balducci, G Slama, J Rottembourg, A Baumelou, A Delage.   

Abstract

The kinetics of absorption of intraperitoneally administered insulin were studied in nine uraemic insulin-dependent diabetics undergoing continuous ambulatory peritoneal dialysis (CAPD). In each of three studies 20 U of regular insulin was directly injected as a bolus into the peritoneal cavity through an indwelling Tenckhoff catheter. In two procedures the insulin injection was followed by the instillation of either 2 litres of 1.5% dextrose dialysates or 2 litres of 4.5% dextrose dialysate. In the third 20 ml of saline was used to flush the tubing. Plasma free insulin values rose more rapidly and reached significantly higher concentrations (55.6 +/- 18.8 mU/l) when the insulin had been injected into an empty peritoneal cavity than when it was followed by dialysate. These differences were observed despite the fact that most of the insulin injected was retained by the patients. Since the plasma insulin values did not differ after instillations of dialysate containing 1.5% and 4.5% dextrose, the osmolality of the dialysate seemed not to affect insulin absorption, and the dilution of the insulin probably delayed its transfer through the peritoneum. These findings suggest that insulin given intraperitoneally to patients undergoing CAPD will be most effective if it is given into an empty peritoneal cavity at least 30 minutes before the dialysate is instilled.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794746      PMCID: PMC1507244          DOI: 10.1136/bmj.283.6298.1021

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  16 in total

1.  Hyperglycemia and hyperosmolality complicating peritoneal dialysis.

Authors:  J Boyer; G N Gill; F H Epstein
Journal:  Ann Intern Med       Date:  1967-09       Impact factor: 25.391

2.  Intraperitoneal insulin with CAPD - an artificial pancreas.

Authors:  C T Flynn; J A Nanson
Journal:  Trans Am Soc Artif Intern Organs       Date:  1979

3.  The intravenous, intraperitoneal, and subcutaneous routes of insulin delivery in diabetic man.

Authors:  D S Schade; R P Eaton; N Friedman; W Spencer
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

4.  Plasma insulin and C-peptide levels during continuous subcutaneous insulin infusion.

Authors:  G Slama; K N Buu; G Tchobroutsky; A Delage; N Desplanque
Journal:  Diabetes Care       Date:  1979 May-Jun       Impact factor: 19.112

5.  Absorption and action of insulin added to peritoneal dialysate in dogs.

Authors:  D J Shapiro; M J Blumenkrantz; S R Levin; J W Coburn
Journal:  Nephron       Date:  1979       Impact factor: 2.847

6.  Haemo- and peritoneal dialysis treatment of patients with diabetic nephropathy--a comparative study.

Authors:  E Quelhorst; B Schuenemann; G Mietzsch; I Jacob
Journal:  Proc Eur Dial Transplant Assoc       Date:  1978

7.  The peritoneal absorption of insulin in diabetic man: a potential site for a mechanical insulin delivery system.

Authors:  D S Schade; R P Eaton; W Spencer; R Goldman; W T Corbett
Journal:  Metabolism       Date:  1979-03       Impact factor: 8.694

8.  Comparison of intraperitoneal, intraportal and intravenous insulin infusion.

Authors:  J S Poulsen; M Smith; M Deckert; T Deckert
Journal:  Acta Endocrinol (Copenh)       Date:  1980-12

9.  The use of the artificial pancreas in uremic diabetic patients.

Authors:  G Slama; J C Klein; A Delage; J Rottembourg; A Marouani; C Jacobs
Journal:  Horm Metab Res Suppl       Date:  1979

10.  Continuous ambulatory peritoneal dialysis.

Authors:  R P Popovich; J W Moncrief; K D Nolph; A J Ghods; Z J Twardowski; W K Pyle
Journal:  Ann Intern Med       Date:  1978-04       Impact factor: 25.391

View more
  1 in total

Review 1.  Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  C A Taylor; E Abdel-Rahman; S W Zimmerman; C A Johnson
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.